Herpes Zoster
📧 Sign up to get email alerts when something new happens for Herpes Zoster.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-12-22Clinical Trial Update: A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia [Phase 3]
Phase 3 trial comparing FV-100 to Valacyclovir for preventing post-herpetic neuralgia was terminated.
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A [Phase 2]
A Phase 2 study of GlaxoSmithKline Biologicals' herpes zoster vaccine (1437173A) completed with results on safety and immunogenicity posted.
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years [Phase 2]
Phase 2 immunogenicity and safety study of GSK's herpes zoster vaccine in adults 50+ completed; results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) [Phase 3]
Phase 3 trial update assessing immunogenicity and safety of ZOSTAVAX given intramuscularly or subcutaneously in adults aged 50 and older; st…
-
CLINICAL_TRIALS research · 2017-11-20Clinical Trial Update: Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older [Phase 3]
A Phase 3 trial assessing the efficacy, safety, and immunogenicity of GSK's Herpes Zoster vaccine in adults aged 70 and older; study complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluating the efficacy and safety of a 5% lidocaine patch versus placebo for herpes zoster-associated pain.
-
CLINICAL_TRIALS trial_result · 2017-10-05Clinical Trial Update: Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects [Phase 2]
A Phase 2 study evaluated long-term immune responses and safety of GSK's herpes zoster vaccine in healthy adults. Results were posted after …
-
CLINICAL_TRIALS trial_result · 2017-09-26Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of GlaxoSmithKline's HZ/su vaccine in adults 65+ with or without prior Zostavax vaccinati…
-
CLINICAL_TRIALS trial_result · 2017-09-26Clinical Trial Update: Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) [Phase 4]
Phase 4 trial update on Zostavax nearing expiry of minimum release specification; results posted after completion.
-
FDA approval · 2017-08-16FDA Approved: ACYCLOVIR — Original Application (Carlsbad Technology, Inc.)
FDA approves a generic acyclovir product under an Original Application (ANDA) from Carlsbad Technology, Inc.
-
CLINICAL_TRIALS trial_result · 2017-08-04Clinical Trial Update: Tzanck Smear With Methylene Blue Stain for Herpes [Phase 3]
A Phase 3 clinical trial evaluating Tzanck smear with methylene blue stain for herpes diagnosis is currently in unknown status.
-
FDA approval · 2017-07-31FDA Approved: ACYCLOVIR — Original Application (Northstar Rx LLC)
FDA approved Northstar Rx LLC's acyclovir as a generic under an original ANDA, authorizing its sale as a generic acyclovir product. The appr…
-
CLINICAL_TRIALS trial_result · 2017-07-19Clinical Trial Update: Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine
An update on cytokine production and immune responses to Varicella Zoster Virus in elderly recipients of the zoster vaccine; the trial statu…
-
CLINICAL_TRIALS trial_result · 2017-07-19Clinical Trial Update: Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ [Phase 4]
Phase 4 clinical trial update evaluating the cell-mediated immune response to Zostavax in cirrhotic subjects. The study notes herpes zoster …
-
CLINICAL_TRIALS trial_result · 2017-07-05Clinical Trial Update: Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of GSK's Herpes Zoster vaccine co-administered with Pneumovax 23 in adults 50+; study com…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects [Phase 2]
Phase 2 trial evaluating GSK1437173A herpes zoster vaccine in HIV-infected adults; study completed and results posted.
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers [Phase 3]
Phase 3 study evaluating the safety and immunogenicity of GlaxoSmithKline's herpes zoster subunit vaccine in adults 18 and older with hemato…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age [Phase 3]
Phase 3 trial update assessing consistency, immunogenicity, and safety of GSK's herpes zoster vaccine in adults 50 and older; study complete…
-
CLINICAL_TRIALS trial_result · 2017-05-01Clinical Trial Update: Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older [Phase 3]
A Phase 3 trial evaluating efficacy, safety, and immunogenicity of GSK's herpes zoster vaccine in adults 50+ completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2017-04-20Clinical Trial Update: Safety Study of NBP608 in Healthy Adult Volunteers [Phase 1]
Phase 1 safety study of NBP608 in healthy adult volunteers has completed; the trial assesses safety and tolerability in contexts related to …
-
CLINICAL_TRIALS trial_result · 2017-04-19Clinical Trial Update: Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over [Phase 3]
A Phase 3 trial comparing the immunogenicity and safety of NBP608 with Zostavax in healthy adults aged 50 and older has completed.
-
CLINICAL_TRIALS research · 2017-04-19Clinical Trial Update: Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia [NA]
A clinical trial evaluating whether early oxycodone use during the acute phase of herpes zoster can prevent postherpetic neuralgia; the stat…
-
CLINICAL_TRIALS trial_result · 2017-04-17Clinical Trial Update: Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over [Phase 2, Phase 3]
Phase 2/3 trial update comparing two lots of NBP608 to Zostavax, assessing immunogenicity and safety in healthy adults aged 50 and over for …
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older [Phase 3]
Phase 3 trial update assessing safety and immunogenicity of different dosing schedules for GSK's herpes zoster vaccine in adults 50+.
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, and the body's ability to develop resistance to an investigational shingles vaccine …